Pancreatic Cancer Research

ResearcherKansai Medical UniversityActive in the last 2 years

Hideo Baba

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-3474-2550; OpenAlex author ID A5100784506. Sources: OpenAlex.

Their work

Papers
36 (first author 0, last author 19)
Trials
0
Grants
0
Labs led
1
Collaborators
144
Papers, trials and grants by year

2011: 2 papers · 2012: none · 2013: 1 paper · 2014: 2 papers · 2015: 4 papers · 2016: 4 papers · 2017: 1 paper · 2018: 3 papers · 2019: 3 papers · 2020: 3 papers · 2021: 3 papers · 2022: 3 papers · 2023: 5 papers · 2024: 2 papers

Papers 36

  1. Prognostic impact of tumor marker kinetics and normalization during neoadjuvant chemotherapy for pancreatic cancer. Last author DOI 10.21037/hbsn-23-662↗
  2. Combined Neutrophil-to-Lymphocyte Ratio Score Is Associated With Chemotherapeutic Response and Predicts Prognosis in Patients With Advanced Pancreatic Cancer. Co-author DOI 10.21873/anticanres.16955↗
  3. Effect of duration of adjuvant chemotherapy with S-1 (6 versus 12 months) for resected pancreatic cancer: the multicenter clinical randomized phase II postoper… Co-author DOI 10.1007/s10147-023-02399-7↗
  4. Hyperglycaemia induces metabolic reprogramming into a glycolytic phenotype and promotes epithelial-mesenchymal transitions via YAP/TAZ-Hedgehog signalling axis… Last author DOI 10.1038/s41416-022-02106-9↗
  5. Intratumoral Malasseziaglobosa Levels Predict Survival and Therapeutic Response to Adjuvant Chemotherapy in Patients With Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1053/j.gastro.2023.04.017↗
  6. The Prognostic Role of Serine Racemase in Patients With Pancreatic Cancer: A New Marker in Cancer Metabolism. Last author DOI 10.1097/mpa.0000000000002210↗
  7. Cancer-associated fibroblasts reuse cancer-derived lactate to maintain a fibrotic and immunosuppressive microenvironment in pancreatic cancer. Co-author DOI 10.1172/jci.insight.163022↗
  8. Thrombospondin-1 overexpression stimulates loss of Smad4 and accelerates malignant behavior via TGF-β signal activation in pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.tranon.2022.101533↗
  9. Identification of Serum miRNA Signature and Establishment of a Nomogram for Risk Stratification in Patients With Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/sla.0000000000003945↗
  10. Tumor microenvironmental 15-PGDH depletion promotes fibrotic tumor formation and angiogenesis in pancreatic cancer. Co-author DOI 10.1111/cas.15495↗
  11. Recent advances in precision medicine for pancreatic ductal adenocarcinoma. Last author DOI 10.1002/ags3.12436↗
  12. Toward an Optimized Staging System for Pancreatic Ductal Adenocarcinoma: A Clinically Interpretable, Artificial Intelligence-Based Model. Co-author DOI 10.1200/cci.21.00001↗
  13. High ARHGEF2 (GEF-H1) Expression is Associated with Poor Prognosis Via Cell Cycle Regulation in Patients with Pancreatic Cancer. Last author DOI 10.1245/s10434-020-09383-9↗
  14. Postoperative nonalcoholic fatty liver disease is correlated with malnutrition leading to an unpreferable clinical course for pancreatic cancer patients underg… Last author DOI 10.1007/s00595-019-01866-x↗
  15. A 15-Gene Immune, Stromal, and Proliferation Gene Signature that Significantly Associates with Poor Survival in Patients with Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-19-4044↗
  16. Prognostic Impact of Coagulation Activity in Patients Undergoing Curative Resection for Pancreatic Ductal Adenocarcinoma. Last author DOI 10.21873/invivo.12111↗
  17. Conversion surgery for initially unresectable pancreatic ductal adenocarcinoma with synchronous liver metastasis after treatment with FOLFIRINOX. Co-author DOI 10.1007/s12328-019-00965-z↗
  18. PD-L1 expression enhancement by infiltrating macrophage-derived tumor necrosis factor-α leads to poor pancreatic cancer prognosis. Last author DOI 10.1111/cas.13874↗
  19. Cellular Senescence, Represented by Expression of Caveolin-1, in Cancer-Associated Fibroblasts Promotes Tumor Invasion in Pancreatic Cancer. Last author DOI 10.1245/s10434-019-07266-2↗
  20. A Comprehensive Assessment of Accurate Lymph Node Staging and Preoperative Detection in Resected Pancreatic Cancer. Co-author DOI 10.1007/s11605-017-3607-7↗
  21. Downregulation of 15-hydroxyprostaglandin dehydrogenase by interleukin-1β from activated macrophages leads to poor prognosis in pancreatic cancer. Co-author DOI 10.1111/cas.13467↗
  22. Thoracic wall muscle metastasis from pancreatic cancer. Last author DOI 10.1186/s40792-017-0393-0↗
  23. Pancreatic Cancer Arising From the Remnant Pancreas: Is It a Local Recurrence or New Primary Lesion? Last author DOI 10.1097/mpa.0000000000000897↗
  24. Intraoperative blood loss is not a predictor of prognosis for pancreatic cancer. Last author DOI 10.1007/s00595-015-1238-8↗
  25. The diagnostic role of the neutrophil-to-lymphocyte ratio in predicting pancreatic ductal adenocarcinoma in patients with pancreatic diseases. Last author DOI 10.1007/s10147-016-0975-z↗
  26. Immunohistochemical Markers Distinguishing Cholangiocellular Carcinoma (CCC) from Pancreatic Ductal Adenocarcinoma (PDAC) Discovered by Proteomic Analysis of M… Co-author DOI 10.1074/mcp.m115.054585↗
  27. A randomized phase II study of S-1 plus oral leucovorin versus S-1 monotherapy in patients with gemcitabine-refractory advanced pancreatic cancer. Co-author DOI 10.1093/annonc/mdv603↗
  28. Randomised phase II trial of S-1 plus oxaliplatin vs S-1 in patients with gemcitabine-refractory pancreatic cancer. Co-author DOI 10.1038/bjc.2015.103↗
  29. Significance of P-cadherin overexpression and possible mechanism of its regulation in intrahepatic cholangiocarcinoma and pancreatic cancer. Last author DOI 10.1111/cas.12732↗
  30. Impact of Postoperative Weight Loss on Survival After Resection for Pancreatic Cancer. Last author DOI 10.1177/0148607114520992↗
  31. Recurrence 11 years after complete response to gemcitabine, 5-Fluorouracil, and Cisplatin chemotherapy followed by radiotherapy in a patient with advanced panc… Co-author PMID 25964569↗
  32. Influence of preoperative anti-cancer therapy on resectability and perioperative outcomes in patients with pancreatic cancer: project study by the Japanese Soc… Co-author DOI 10.1002/jhbp.15↗
  33. Hepatobiliary and pancreatic: sigmoidal mesenterial lymph node metastasis from pancreatic cancer. Last author DOI 10.1111/jgh.12807↗
  34. Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan… Co-author DOI 10.1200/jco.2012.43.3680↗
  35. Sister Mary Joseph's nodule derived from pancreatic cancer. Last author DOI 10.1007/s00534-010-0296-y↗
  36. Identification of HLA-A2-restricted CTL epitopes of a novel tumour-associated antigen, KIF20A, overexpressed in pancreatic cancer. Co-author DOI 10.1038/sj.bjc.6606052↗

Closest collaborators

The 25 strongest of 144 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Hiromitsu Hayashi · 15 shared papers, 2014–2024 · strength 1.82
  2. Katsunori Imai · 15 shared papers, 2011–2023 · strength 1.41
  3. Shigeki Nakagawa · 11 shared papers, 2015–2023 · strength 1.06
  4. Zhao Liu · 5 shared papers, 2020–2024 · strength 0.84
  5. Hirohisa Okabe · 8 shared papers, 2015–2024 · strength 0.70
  6. Rumi Itoyama · 7 shared papers, 2014–2023 · strength 0.66
  7. Akira Chikamoto · 10 shared papers, 2014–2020 · strength 0.64
  8. Tatsunori Miyata · 5 shared papers, 2019–2023 · strength 0.61
  9. Kosuke Mima · 4 shared papers, 2022–2023 · strength 0.59
  10. Norio Uemura · 4 shared papers, 2020–2023 · strength 0.52
  11. Masayo Tsukamoto · 5 shared papers, 2018–2023 · strength 0.50
  12. Fumimasa Kitamura · 4 shared papers, 2020–2023 · strength 0.47
  13. Kota Arima · 6 shared papers, 2016–2022 · strength 0.45
  14. Ajay Goel · 3 shared papers, 2020–2023 · strength 0.44
  15. Toshiro Masuda · 4 shared papers, 2017–2024 · strength 0.44
  16. Daisuke Hashimoto · 7 shared papers, 2014–2018 · strength 0.43
  17. Takayoshi Kaida · 4 shared papers, 2016–2023 · strength 0.40
  18. Kazuki Matsumura · 3 shared papers, 2020–2023 · strength 0.39
  19. Takatsugu Ishimoto · 4 shared papers, 2018–2023 · strength 0.39
  20. Naoki Umezaki · 4 shared papers, 2018–2021 · strength 0.36
  21. Hiroshi Takamori · 5 shared papers, 2011–2023 · strength 0.36
  22. Takanobu Yamao · 4 shared papers, 2019–2020 · strength 0.36
  23. Kensuke Yamamura · 4 shared papers, 2016–2020 · strength 0.35
  24. Masahiko Hirota · 3 shared papers, 2015–2024 · strength 0.33
  25. Yasuhiro Kodera · 2 shared papers, 2022–2023 · strength 0.32

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.